Sign inCreate account

Report workspace tools

NCT04387630UNKNOWNanonymous

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Sponsor

Source record

Mansoura University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Metformin, Placebo oral tablet

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Metformin, Placebo oral tablet

Source & freshness

Source record

NCT ID

NCT04387630

Original source

ClinicalTrials.gov

Source last updated

Jun 11, 2020

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04387630

Title

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Sponsor

Mansoura University

Status

UNKNOWN

Phase

PHASE2

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Metformin, Placebo oral tablet

Target normalized

Metformin, Placebo oral tablet

Interventions

Metformin, Placebo oral tablet

Public preview

Source record

Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04387630

Status

UNKNOWN

Phase

PHASE2

Sponsor

Mansoura University

Executive brief

Investment-Ready Snapshot

Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 11, 2020
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04387630

Indication

Breast Cancer

Modality

small molecule

Target

Metformin, Placebo oral tablet

Intervention

Metformin, Placebo oral tablet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.